The expression of osteopontin in breast cancer tissue and its relationship with p21ras and CD44V6 expression

Objective: This study aimed to investigate the expression of osteopontin (OPN), p21ras, and CD44V6 in breast cancer tissues, and to analyze the relationships between their expression and a patient's clinicopathological characteristics and five-year survival rate. Materials and Methods: Streptavidin-peroxidase immunohistochemistry was used to detect the expression of OPN, p21ras, and CD44V6 in tissue samples from 96 breast cancer patients, and the multivariate Cox proportional hazards model (mCOX-PHM) was used to analyze the factors that affect prognosis. Results: Among the 96 breast cancer patients studied, positive staining for OPN, CD44V6, and p21ras was observed in 54.2%, 58.3%, and 43.8% of samples, respectively. The expression of OPN and CD44V6 were positively correlated (r = 0.58), and the expression of OPN and p21ras were also positively correlated (r = 0.25). Coexpression OPN, CD44V6, and p21ras was negatively correlated with a patient's five-year survival rate (p < 0.05). Kaplan-Meier analysis indicated that a patient without OPN, CD44V6, or p21ras expression had an improved survival (p < 0.05). Results from the mCOX-PHM analysis indicated that CD44V6 expression, the degree of tumor differentiation, and lymph node metastasis were all independent factors that indicate prognosis. The combined detection of OPN, CD44V6, and p21ras could contribute to a more accurate assessment of the biological behavior of breast cancers, and could help to indicate the prognosis of breast cancer patients.

OPN; P21ras; CD44V6; Breast cancer.

[1] Desantis C., Ma J., Bryan L., Jemal A.: “Breast cancer statistics, 2013”. CA. Cancer J. Clin., 2014, 64, 52.

[2] Anborgh PH., Mutrie JC., Tuck AB., Chambers AF.: “Pre- and posttranslational regulation of osteopontin in cancer”. J. Cell Commun. Signal., 2011, 5, 111.

[3] Jain S., Chakraborty G., Kundu GC.: “The crucial role of cyclooxygenase-2 in osteopontin-induced protein kinase c alpha/c-src/ikappabkinase alpha/beta-dependent prostate tumor progression and angiogenesis”. Cancer Res., 2006, 66, 6638.

[4] Chen RX., Xia YH., Xue TC., Zhang H., Ye SL.: “Down-regulation of osteopontin inhibits metastasis of hepatocellular carcinoma cells via a mechanism involving mmp-2 and upa”. Oncol. Rep., 2011, 25, 803.

[5] Zhao B., Sun T., Meng F., Qu A., Li C., Shen H., et al.: “Osteopontin as a potential biomarker of proliferation and invasiveness for lung cancer”. J. Cancer Res. Clin. Oncol., 2011, 137, 1061.

[6] Chung CU., Soma K., Rittling SR., Denhardt DT., Hayata T., Nakashima K., et al.: “OPN deficiency suppresses appearance of odontoclastic cells and resorption of the tooth root induced by experimental force application”. J. Cell. Physiol., 2008, 214, 614.

[7] Rittling SR.: “Osteopontin in macrophage function”. Expert Rev. Mol. Med., 2011, 13, el5.

[8] Wang KX., Denhardt DT.: “Osteopontin: role in immune regulation ang stress responses”. Cytokine Growth Factor Rev., 2008, 19, 333.

[9] Liu SJ., Zhang DQ., Sui XM., Zhang L., Cai ZW., Sun LQ., et al.: “The inhibition of in vivio tumorigenesis of osteosarcoma (OS)-732 cells by antisense human osteopontin RNA”. Cell. Mol. Biol. Lett., 2008, 13, 11.

[10] Hotte SJ., Winquist EW., Lamont E., MacKenzie M., Vokes E., Chen EX., et al.: “Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expression c-kit: a Princess Margaret Hospital phase II consortium study”. J. Clin. Oncol., 2005, 23, 585.

[11] Ailane S., Long P., Jenner P., Rose S.: “Expression of integrin and cd44 receptors recognising osteopontin in the normal and lps-lesioned rat substantia nigra”. Eur. J. Neurosci., 2013, 38, 2468.

[12] Collins AL., Rock J., Malhotra L.: “Osteopontin expression is associated with improved survival in patients with pancreatic adenocarcinoma”. Ann. Surg. Oncol., 2012, 19, 2673.

[13] Thorat D., Sahu A., Behera R.: “Association of osteopontin and cyclooxygenase-2 expression with breast cancer subtypes and their use as potential biomarkers”. Oncol. Lett., 2013, 6, 1559.

[14] Li NY., Weber CE., Mi Z., Wai PY., Cuevas BD., Kuo PC.: “Osteopntin up-regulates crithelial-mesenchymal transition transcription factors to induce an aggressivebreast cancer phenotype”. J. Am. Coll. Surg., 2013, 217, 17.

[15] Wang G., Platthiggin A., Carroll J., de Silva Rudland S., Winstanley J., Barraclough R., et al.: “Induction of metastesis by S100P in a rat mammary model and its association with poor suivival of breast cancer patients”. Cancer Res., 2006, 66, 1199

[16] Tókés AM., Krausz J., Kulka J., Jäckel M., Kádár A.: “Role of osteopontin in the Formation of Micro-calcifications in the breast cancer”. Orv. Hetil., 2002, 143, 1841

[17] Hedley BD., Welch DR., Allan AL., Al-Katib W., Dales DW., Postenka CO., et al.: “Downregulation of osteopontin contributes to metastasis suppression by breast cancer metastasis suppressor 1”. Int. Cancer, 2008, 123, 526.

[18] Rudland PS., Platt-Higgins A., El-Tanani M., De Silva Rudland S., Barraclough R., Winstanley JH., et al.: “Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer”. Cancer Res., 2002, 62, 3417.

[19] Kumar V., Behera R., Lohite K., Karnik S., Kundu GC.: “P38 kinase is crucial for osteopontin-induced furin expression that supports cervical cancer progression”. Cancer Res., 2010, 70, 10381.

[20] Ortiz-Martínez F., Perez-Balaguer A., Ciprián D., Andrés L., Ponce J., Adrover E., et al.: “Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence”. Hum. Pathol., 2014, 45, 504.

[21] Borges K., Gearing M., Rittling S., Sorensen ES., Kotloski R., Denhardt DT., et al.: “Characterization of osteopontin expression and function after status epilepticus”. Epilepsia, 2008, 49, 1675.

[22] Furger KA., Allan AL.,Wilson SM., Hota C., Vantyghem SA., Postenka CO., et al.: “Beta 3 integrin expression increases breast carcinoma cell responsiveness to the Malignancy-enhancing effects of osteopontin”. Mol. Cancer Res., 2003, 1, 810.

[23] Gao C., Mi Z., Guo H., Kuo PC.: “Osteopontin regulates ubiquitin-dependent degradation of Stat1 in mrine mammary epithelial tumor cells”. Neoplasia, 2007, 9, 699.

[24] Orian-Rousseau V., Ponta H.: “Adhesion proteins meet receptors: a common theme? Adv. Cancer Res., 2008, 101, 63.

[25] Krishnamachary B., Penet MF., Nimmagadda S., Mironchik Y., Raman V., Solaiyappan M., et al.: “Hypoxia regulates CD44 and its variant isoforms through HIF-1α in triple negative breast cancer”. PLoS One, 2012, 7, e44078.

[26] Tokue Y., Matsumura Y., Katsumata NM., Watanabe T., Tarin D., Kakizoe T.: “CD44 variant isoform expression and breast cancer prognosis”. Jpn. J. Cancer Res., 1998, 89, 283.

[27] Diaz LK., Zhou X., Wright ET., Cristofanilli M., Smith T., Yang Y., et al.: “CD44 expression is associated with increased survival in nodenegative invasive Breast carcinoma”. Clin. Cancer Res., 2005, 11, 3309.

[28] Afify A., McNiel MA., Braggin J., Bailey H., Paulino AF.: “Expression of CD44s, CD44v6, and hyaluronan across the spectrum of normal-hyperplasia-carcinoma in breast”. Appl. Immunohistochem. Mol. Morphol., 2008, 16, 121.

[29] Heider KH., Kuthan H., Stehle G., Munzert G.: “CD44V6: a target for antibody-based cancet therapy”. Cancer Immunol. Immunother., 2004, 53, 567.

[30] Bankfalvi A., Terpe H J., Breukelmann D., Bier B., Rempe D., Pschadka G., et al.: “Gains and losses of CD44 expression during breast carcinogenesis and tumour progission”. Histopathology, 1998, 32, 107.

[31] Ma W., Deng Y., Zhou L.: “The prognostic value of adhesion molecule CD44v6 in women with primary breast carcinoma: a clinico-pathologic study”. Clin. Oncol. (R. Coll. Radiol.), 2005, 17, 258.

[32] Lian ZQ., Yang MT., Hou JH., Luo RZ., Wang X., Tang J.: “Expression and clinical significance of adhesive molecule CD44v6 in breast invasive ductal carcinoma”. Ai Zheng, 2006, 25, 1291.

[33] Shah NG., Trivedi TI., Vora HH.: “CD44v6 expression in primary breast carcinoma in western India: a pilot clinicopathologic study”. Tumori, 2010, 96, 971.

[34] Guarino V., Faviana P., Salvatore G., Castellone MD., Cirafici AM., De Falco V., et al.: “Osteopontin is over-expressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness”. J. Clin. Endocrinol. Metab., 2005, 90, 5270.

[35] Johnston NI., Gunasekharan VK., Ravindranath A., O’Connell C., Johnston PG., El-Tanani MK.: “Osteopontin as a target for cancer therapy”. Front. Biosci., 2008, 13, 4361.